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insect poxvirus (Petersen et al., 1997). The poxvirus to-
poisomerases are of fairly uniform size (314to 333 amino
acids) and are considerably smaller than the cellular
counterparts. This suggests that the viral topoisomer-
ases constitute the minimal functional unit of a type IB
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We have focused on the 314±amino acid vaccinia to-
poisomerase as the prototype of the type IB family. The
vaccinia protein binds and cleaves duplex DNA at a
Summary specific target sequence 59-(T/C)CCTT↓ (Shuman and
Prescott, 1990; Shuman, 1991a). The T↓ nucleotide is
Vaccinia DNA topoisomerase breaks and rejoins DNA linked to Tyr-274 of the enzyme (Shuman et al., 1989).
strands through a DNA-(39-phosphotyrosyl)-enzyme The active site tyrosine resides within a motif, SKxxY,
intermediate. A C-terminal catalytic domain, Topo(81± that is located near the C terminus of all type IB family
314), suffices for transesterification chemistry. The do- members (Eng et al., 1989; Lynn et al., 1989; Caron and
main contains a constellation of five amino acids, con- Wang, 1994). The vaccinia topoisomerase consists of
served in all eukaryotic type IB topoisomerases, that two domains joined through a trypsin-sensitive bridge
catalyzes attack of the tyrosine nucleophile on the (Sharma et al., 1994; Sekiguchi and Shuman, 1995) (Fig-
scissile phosphate. The structure of the catalytic do- ure 1). The N-terminal domain (aa 1±80) includes two
main, consisting of ten a helices and a three-strand b amino acids, Tyr-70 and Tyr-72, that contact the 14C
sheet, resembles the catalytic domains of site-specific and 13C bases of the CCCTT element in the major
recombinases that act via a topoisomerase IB-like groove (Sekiguchi and Shuman, 1996a). The sequence
mechanism. The topoisomerase catalytic pentad is of the N-terminaldomain isconserved among topoisom-
conserved in the tertiary structures of the recombi- erases encoded by vertebrate and invertebrate poxvi-
ruses, which bind and cleave specifically at the CCCTTnases despite scant sequence similarity overall. This
sequence (Petersen et al., 1997). The structure of theimplies that the catalytic domains of type IB topoisom-
N-terminal tryptic fragment has been determined byerases and recombinases derive from a common an-
X-ray crystallography (Sharma et al., 1994) and modeledcestral strand transferase.
into the major groove of CCCTT based on contacts de-
fined by photo-cross-linking (Sekiguchi and Shuman,Introduction
1996a). The analogous segment of cellular type IB topo-
isomerases is divergent in sequence and structure fromEukaryotic type I topoisomerases (now called type IB
the vaccinia domain (Lue et al., 1995). Cellular topoisom-
topoisomerases) play important roles inDNA replication,
erases exhibit a loose preference for cleavage at a
recombination, and transcription (Wang, 1996). In addi-
4-base motif, 59-(A/T)(G/C)(A/T)T↓ (Jaxel et al., 1991).
tion, they are promising targets for cancer chemother- The 234±amino acid carboxyl segment Topo(81±314)
apy (Rothenberg, 1997). Type IB topoisomerases relax is an autonomous catalytic domain that performs the
positive and negative supercoils via a reaction pathway same repertoire of reactions as the full-sized vaccinia
that entails (i) noncovalent binding of the topoisomerase topoisomerase: relaxationof supercoiled DNA, site-spe-
to duplex DNA, (ii) cleavage of one DNA strand with con- cific DNA transesterification, and DNA strand transfer
comitant formation of a covalent DNA-(39-phosphotyro- (Cheng and Shuman, 1998). A kinetic comparison of
syl)-protein intermediate, (iii) rotation of the noncovalently the full-length enzyme and Topo(81±314) showed that
held duplex segment about the phosphodiester bond in elimination of the N-terminal domain slows the rate of
the unbroken strand opposite the protein-induced nick, single-turnover DNA cleavage but has little effect on
and (iv) religation to the 59 OH end of the cleaved strand. the rate of single-turnover DNA religation. Topo(81±314)
The type IB enzymes can also transfer the covalently also has lower affinity for noncovalent binding to the
held strand to a heterologous polynucleotide to generate CCCTT target site. Identical properties are displayed by
recombinant molecules. a full-length mutant protein, Topo(Y70A-Y72A), which
The type IB topoisomerase family includes the nuclear lacks two tyrosine side chains within the N-terminal do-
topoisomerase I found in all eukaryotic cells and the main that contact the CCCTT site in the major groove
(Cheng and Shuman, 1998). We proposed that Topo(81±topoisomerases encoded by vaccinia and other cyto-
314) is fully competent for transesterification chemistry,plasmic poxviruses. Genes encoding type IB topoisom-
but is compromised with respect to a rate-limiting pre-erases have now been identified from more than a dozen
cleavage conformational step that is contingent on DNAcellular sources; the proteins vary in size from 765 to
contacts made by residues within the N-terminal domain1019 amino acids (Caron and Wang, 1994; Gupta et al.,
(Cheng and Shuman, 1998).1995). Viral topoisomerase genes have been cloned from
The amino acid sequence of the vaccinia catalyticfive different genera of vertebrate poxviruses and one
domain is conserved in other poxvirus-encoded en-
zymes and in the cellular type I topoisomerases (Figure
1). In order to identify themoieties responsible for cataly-³To whom correspondence should be addressed.
§These authors contributed equally to this work. sis of strand cleavage and rejoining, we have performed
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Figure 1. Conserved Catalytic Domain of Vaccinia Topoisomerase
The domain structure of the 314±amino acid vaccinia topoisomerase is illustrated. The active site Tyr-274 is indicated. The amino acid sequence
of the vaccinia virus (vv) topoisomerase catalytic domain (residues 81 to 314) is aligned with the homologous segments of viral topoisomerases
encoded by Shope fibroma virus (sf), molluscum contagiosum virus (mc), orf virus (ov), fowlpox virus (fp), and entomopoxvirus (ep) and with
the cellular type I topoisomerase of Saccharomyces cerevisiae (Sc). Sequence gaps are indicated by dashes. Residues conserved among
the poxvirus topoisomerases are demarcated by the shaded boxes, as are those residues shared with the yeast enzyme. Conserved residues
identified by mutagenesis as being important for DNA cleavage or religation chemistry are denoted by arrowheads. The protease-sensitive
region within the catalytic domain of vaccinia topoisomerase (aa 135±147) is demarcated by a horizontal bar above the sequence. The cellular
topoisomerases contain a nonconserved linker inserted between His-265 and Tyr-274 (denoted by a triangle below the yeast sequence).
a comprehensive structure-function analysis of the vac- the topoisomerase and recombinase structures. We hy-
pothesize (i) that the catalytic domains of eukaryoticcinia topoisomerase entailing site-directed mutagenesis
of .140 individual residues. We have identified five type IB topoisomerase and site-specific recombinases
have evolved from an ancestral strand transferase andamino acid side chains (other than the active site tyro-
sine) that participate in transesterification chemistry and (ii) that biological specificity is conferred (at least in part)
by structurally divergent amino-terminal domains.are conserved in every member of the type IB family
(Figure 1). Arg-130, Lys-167, Lys-220, Arg-223, and His-
265 enhance the transesterification rate by factors of
105, 104, 101, 105, and 102, respectively (Morham and Results and Discussion
Shuman, 1990, 1992; Wittschieben and Shuman, 1994;
Petersen et al., 1996; Cheng et al., 1997; Petersen and Structure of the Topoisomerase Catalytic Domain
Earlier probing of the native solution structure of vac-Shuman, 1997; Wang et al., 1997; Wittschieben and Shu-
man, 1997). It is proposed that these residues catalyze cinia topoisomerase by limited proteolysis showed that
the C-terminal catalytic domain contains a protease-the attack of Tyr-274 on the scissile phosphate through
transition state stabilization and general acid catalysis sensitive region from residues 135±147 (Figure 1). The
enzyme is cleaved by trypsin at Lys-135, by chymotryp-of theexpulsion of the 59 OH leaving group (Wittschieben
and Shuman, 1997). Three other residues, Gly-132, Tyr- sin primarily at Tyr-136 and secondarily at Leu-146, and
by V8 protease at Glu-139 and Glu-141 (Sharma et al.,136, and Ser-204, which are important for strand cleav-
age but not for religation, are implicated in a proposed 1994; Sekiguchi and Shuman, 1995). The protein seg-
ments flanking the protease-sensitive region remainprecleavage conformational step (Wang et al., 1997;
Wittschieben and Shuman, 1997). physically associated after scission of the Tyr-136/Leu-
137 peptide bond by chymotrypsin (Sekiguchi and Shu-Here we report the crystallization of Topo(81±314) and
the determination of its structure. The catalytic domain man, 1995). In contrast, the N-terminal domain (aa 1±80)
dissociates from the rest of the protein after limitedof eukaryotic topoisomerase is structurally similar to the
catalytic domains of HP1 integrase, Cre recombinase, digestion with trypsin (Sharma et al., 1994). These re-
sults, together with the recent finding that Topo(81±314)and other site-specific recombinases that catalyze strand
breakage and rejoining through covalent DNA-(39-phos- is enzymatically active, suggest that the catalytic do-
main Topo(81±314) is a single structural unit punctuatedphotyrosyl)-enzyme intermediates. Residues essential
for reaction chemistry occupy homologous positions in by a segment that may be flexible or loosely folded.
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Table 1. Statistics from the Crystallographic Analysis
Data Collection
Reflections
MIR Analysis
Data Rsyma Phasing
Data Set Resolution (AÊ ) Measured Unique Coverage (%) (%) MFIDb Powerc
Native (CHESS) 2.3 114,536 13,123 96.1 4.9
Thimerosal 3.0 22,453 5,066 83.1 6.9 0.19 1.5
KAu(CN)2 2.8 20,936 6,625 88.4 5.6 0.22 2.2
HgCl2 2.8 20,127 7,304 90.0 4.8 0.20 1.8
Refinement Statistics
RMSf
Resolution Reflections Protein Water R Factord Rfreee Bonds Angles B Factors
(AÊ ) (with F . 3s) Atoms Atoms (%) (%) (AÊ ) (8) (AÊ 2)
Native 20.0±2.3 11,506 1,706 164 22.7 30.9 0.014 1.908 3.9
a Rsym 5 ShS i|Ih,i 2 Ih|ShSiIh,i for the intensity (I) of i observations of reflection h.
b MFID: mean isomorphous difference 5 S|FPH 2 FP|SFPH, where FPH and FP are the derivative and native structure factors, respectively.
c Phasing power 5 [(FH(calc)2/(FPH(obs) 2 FPH(calc))2]1/2.
d R factor 5 S|Fo 2 Fc|/S|Fo|, where Fo and Fc are the observed and calculated structure factors, respectively.
e Free R factor calculated from 5% of the data chosen randomly and omitted from simulated annealing refinement.
f Root-mean-square deviations from ideal geometry and root-mean-square variation in the B factors of bonded atoms.
To gain further insight into the topoisomerase struc- crystals, the N-terminal lobe (aa 81±210) has an overall
temperature factor of 57 AÊ 2, which is significantly higherture, we purified and crystallized Topo(81±314). Details
of the structure determination and refinement are in- than the 37 AÊ 2 temperature factor of the C-terminal lobe
(aa 211±310). Accordingly, the electron density of thecluded in Table 1. The final model included 221 of the
234 amino acids of the protein (Figure 2). Four amino N-terminal lobe, and the b sheet in particular, is of lower
quality than that of the C-terminal lobe. The apparentacids at the C terminus had no interpretable electron
density; we showed previously that deletion of these lower order of the b-sheet region is reflected in the
refinement statistics.The N-terminal lobe does not makeresidues has no effect on topoisomerase activity (Wang
and Shuman, 1997). There was also no interpretable significant crystal packing contacts, and we presume
this contributes to its high temperature factors.electron density from residues 129 to 137; this is consis-
tent with the idea that the protease-sensitive segment
is poorly structured in the free enzyme. The catalytic
domain is an oblong-shaped globular protein with di- Structural Similarity to Site-Specific Recombinases
A search of the structures available in the Protein Datamensions of 56 3 28 3 26 AÊ . It consists of ten a helices
and a three-stranded antiparallel b sheet on one surface Bank using the program DALI (Holm and Sander, 1993)
showed that the fold of the vaccinia topoisomerase cata-(Figure 2). An N-terminal lobe (colored purple in Figure
2) comprises helices 1±5 and the b sheet; a C-terminal lytic domain was quite similar to the fold of the catalytic
domains of bacteriophage HP1 integrase and lambdalobe (colored cyan) consists of helices 6±10. The long
N-terminal a helix is integrated into both lobes. In the integrase (Hickman et al., 1997; Kwon et al., 1997). These
Figure 2. Overall Fold of the Topoisomerase
Catalytic Domain
The figure was prepared with the program
MOLSCRIPT (Kraulis, 1991). The amino lobe
of the protein (consisting of helices 1±3, a
three-strand b sheet, and helices 4 and 5) is
colored in purple; the carboxyl lobe (con-
sisting of helices 6±10) is colored in cyan.
Two anomalous electron density peaks that
likely correspond to enzyme-bound sulfates
are shown in red. Amino acid side chains that
coordinate the sulfates (Arg-84, His-265, Ser-
268, Ser-270, and Lys-271) are colored in yel-
low. Residues 129±137 that are not defined in
the structure are depicted as a dashed purple
line connecting helices 2 and 3.
Cell
844
Figure 3. Structural Conservation between Topoisomerase and Recombinases
The secondary structure of vaccinia topoisomerase is shown above its amino acid sequence. The polypeptide backbone of topoisomerase
was aligned to the backbones of HP1 integrase (A) and Cre recombinase (B) using the program O. Gaps in the structure-based alignment are
indicated by dashes. Amino acid identity (asterisks) and similarity (carets) are denoted below the aligned sequences. The Tyr nucleophile
(helix 8) and other amino acids implicated in catalysis are in highlighted in shaded boxes. The vaccinia segment from amino acids 129±137
not seen in the crystal structure (denoted by a gap in the secondary structure) was aligned to HP1 and Cre according to the location of the
catalytic Arg residue (shaded box).
two proteins are members of a large family of site-spe- of 7±9 a helices with a three-stranded b sheet (Kwon
et al., 1997; Subramanya et al., 1997; Yang and Mizuuchi,cific recombinases that catalyze reciprocal DNA strand
transfer reactions during the formation and resolution 1997). Note that there is little amino acid sequence
similarity between the recombinase family membersof four-strand Holliday junctions. The 20 kDa C-terminal
fragment of HP1 integrase consists of nine a helices themselves, and structure-based alignments of the re-
combinases are punctuated by frequent deletions andwith a three-stranded antiparallel b sheet on one side
(Hickman et al., 1997). The order and topology of the insertions (Yang and Mizuuchi, 1997).
The recombinases are mechanistically related to thesecondary structural elements resembled that of the
topoisomerase domain from the N-terminal helix through eukaryotic type I topoisomerases insofar as they, too,
incise one strand of duplex DNA to yield a free 59 OHhelix 8 (wherein the active site tyrosine resides). The
amino acid sequences of the topoisomerase (aa 92±275) strand and a covalent DNA-(39-phosphotyrosyl)-enzyme
intermediate. Most recombinases display topoisomer-and HP1 integrase (aa 176±316) were aligned based on
a superimposition of homologous segments of the two ase I activity in vitro (Kikuchi and Nash, 1979; Abremski
et al., 1986; Cornet et al., 1997). Therefore, it is moststructures (Figure 3A). Each protein has unique seg-
ments not found in the other; e.g., HP1 integrase con- instructive that the functional moieties of vaccinia to-
poisomerase that are important for transesterificationtains a 10±amino acid segment between helices 5 and
6 not found in topoisomerase, and topoisomerase has chemistry are well conserved in the HP1 integrase and
Cre (Figure 3) and in the two other site-specific recom-a 20±amino acid segment between helices 6 and 7 that
is missing from the integrase (Figure 3A). Of the 130 binases for which structures have been determined:
lambda integrase and XerD recombinase (Yang and Mi-amino acids that we could align, 27 side chains are
identical and 15 are conserved (Figure 3A). zuuchi, 1997). For example, vaccinia residue Lys-167 is
located in the loop connecting the second and thirdConservation of secondary and tertiary structure was
also noted when topoisomerase was superimposed on antiparallel b sheets; a lysine is present at the same
position in HP1 and lambda integrases, Cre, and XerD.the C-terminal catalytic domain of Cre recombinase (aa
139±325), which consists of nine a helices and an anti- Lys-167 is invariant in all eukaryotic type IB topoisomer-
ases; it contributes 103±4 catalytic power to the vacciniaparallel b sheet (Guo et al.,1997; coordinatesgenerously
provided by Dr. Greg Van Duyne) (Figure 3B). Of the 148 enzyme (Petersen et al., 1996; Wittschieben and Shu-
man, 1997). Mutation of the homologous lysine in humanamino acids that we could align, 19 side chains are
identical and 22 are similar. Cre lacks the topoisomerase topoisomerase I also results in loss of activity (Jensen
and Svejstrup, 1996). Thus, we suspect that the homolo-loop between helices 6 and 7, while topoisomerase has
no homolog of the Cre segment between helices 5 and gous lysine side chain is essential for DNA transesterifi-
cation by the recombinases. In the Cre-lox DNA cocrys-6 (Figure 3B). Other recombinases (lambda integrase
and XerD) adopt a similar tertiary structure composed tal, this lysine interacts in the minor groove with the 11
Structure of Eukaryotic Topoisomerase I
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Figure 4. Superimposition of the Topoisomerase and Recombinase Structures from Helices 6±8
(A) Topoisomerase (cyan) versus HP1 integrase (green).
(B) Topoisomerase (cyan) versus Cre recombinase (green).
Topoisomerase residues Lys-220, Arg-223, His-265, and Tyr-274 are colored yellow. The homologous residues of HP1 (His-280, Arg-283, His-
306, and Tyr-315) and Cre (His-289, Arg-292, Trp-315, and Tyr-324 of the noncovalent Cre protomer) are colored red.
base on the scissile strand (i.e., Np↓) and the 12 base substituted by Asn or Gln (which are structural conge-
ners of the His side chain) (Petersen and Shuman, 1997).on the nonscissile strand (Guo et al., 1997).
An RHR triad conserved in all recombinase family It was suggested based on these findings that His-265
might hydrogen bond with the scissile phosphate duringmembers is postulated to activate the scissile phos-
phate for attack by the tyrosine nucleophile. The triad strand cleavage by the topoisomerase. Although the
function of this histidine in recombinase reaction chem-consists of an Arg residue located between helices 2
and 3 of HP1 integrase (this corresponds to the pro- istry has not been dissected by mutagenesis, the struc-
tures of the HP1 integrase and XerD suggest that thetease-sensitive region of vaccinia topoisomerase) and
a His-x-x-Arg motif within helix 6 (Figure 3). Although histidine is poisedto hydrogen bond to the scissile phos-
phate (Hickman et al., 1997; Subramanya et al., 1997).the protease-sensitive region is not resolved in the topo-
isomerase structure, we surmise from primary sequence The analogous residue in Cre recombinase is a trypto-
phan that does indeed hydrogen bond with the scissilealignment that the proximal Arg in the RHR triad is ho-
mologous to vaccinia residue Arg-130, which is invariant phosphate in the Cre-lox enzyme±DNA cocrystal (Guo
et al., 1997; Figure 4B). The Cre-lox structure providesin type IB topoisomerases and contributes 105 catalytic
power to the vaccinia enzyme (Figure 3). A superimposi- definitive evidence that the active site is composed of
an RHRW tetrad of side chains, each of which hydrogention of HP1 integrase, Cre recombinase, and vaccinia
topoisomerase from helices 6 through 8 shows that vac- bonds to the scissile phosphate; the homologous RKRH
residues in vaccinia topoisomerase (R130, K220, R223,cinia residues Lys-220 and Arg-223 are equivalent to
the HxxR component of the recombinase triad (Figure and H265) are all important for reaction chemistry.
4A). Arg-223 accelerates transesterification by 105,
whereas Lys-220 contributes only modestly (10-fold) to The Active Site Tyrosine
The conserved topoisomerase I active site motif SKxxYtopoisomerase reaction chemistry. Both arginines of the
RHR triad are essential for transesterification by lambda is located within helix 8. The experimental MIR maps
and the omit electron density of this portion of the topo-integrase and FLP recombinase (Parsons et al., 1988,
1990; Han et al., 1993). The histidine of the triad is not isomerase structure are shown in Figure 5. The tyrosine
hydroxyl is hydrogen bonded to the carboxylate of Asp-required for strand cleavage by FLP (Parsons et al.,
1988; Lee and Jayaram, 1993). 85 (not shown). The tyrosine side chain is actually ori-
ented away from the putative binding pocket for theEssential residue His-265 of vaccinia topoisomerase
is located 9±amino acids proximal to the active site scissile phosphate that would be formed by the catalyti-
cally essential residues and therefore is not poised totyrosine within a loop linking helices 7 and 8 (Figure 3).
HP1 and lambda integrases and XerD also have histi- engage in catalysis (Figure 4). A similar situation applies
to XerD, where the tyrosine is buried in the protein withdines at this position. The vaccinia and HP1 residues
are located near each other in the tertiary structure (Fig- the hydroxyl moiety pointing away from the putative
phosphate-binding site that includes the conserved ar-ure 4A). Changing vaccinia His-265 to alanine elicits a
100-fold decrement in catalytic activity, but activity is ginines of the RHR triad (Subramanya et al., 1997). In
contrast, the tyrosine nucleophile of HP1 integrase isrestored to near wild-type levels when position 265 is
Cell
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Figure 5. Electron Density
The figure shows the electron density sur-
rounding residues 269±282 contoured at 1.0 s.
(A) The 3.2 AÊ MIR map.
(B) 2Fo-Fc omit map, calculated after omit-
ting residues 269±282 and subjecting the
model to simulated annealing refinement to
reduce model bias.
pointed toward the putative phosphate-binding site chains (the sites on the native enzyme to which BrC-
substituted ligands were cross-linked) (Sekiguchi andformed by the catalytic side chains (Hickman et al.,1997)
Shuman, 1996a). Here we have built a model of the(Figure 4A). We surmise that Tyr-274 must be reoriented
noncovalent topoisomerase±DNA complex by fitting theupon binding of the topoisomerase to the DNA target
structure of the catalytic domain onto the B-form duplexsite.
such that the sulfates are superimposed on the scissileThe anomalous scattering electron density maps sug-
phosphate and 59 proximal phosphate, respectively, ofgested that two sulfate ions were bound to the enzyme,
the CCCTpTp↓N element (Figure 6). This positions thecoordinated by four amino acid side chains within the
carboxyl end of theN-terminal domain structure (residueHTPSISKRAY sequence about the active site Tyr (Figure
77) on the same face of the helix as the start of the2). One sulfate is within hydrogen bonding distance of
catalytic domain (residue 81) such that connectivity ofHis-265, Ser-268, and Lys-271; close to it are the side
the polypeptide could be established by the three resi-chains of Lys-220 and Arg-223. The second sulfate is
dues (aa 78±80) missing from the amino domain struc-coordinated by Ser-268 and Ser-270 as well as Arg-84.
ture. The protein spans an z18 bp DNA segment (fromArg-84 is located within the trypsin-sensitive bridge and
110 to 29 relative to the scissile phosphate), which isits side chain is implicated by mutational analysis in
consistent with the dimensions of the DNase I footprintnoncovalent binding of topoisomerase to theDNA target
(Shuman, 1991a). The model has a number of other vir-(Sekiguchi and Shuman, 1995, 1997). Tyr-274 is pointed
tues that explain and embellish previous biochemicalaway from thesulfates. The distancebetween the sulfate
insights concerning vaccinia topoisomerase. (i) It sug-densities (6.4 AÊ ) is similar to the distancebetween vicinal
gests that topoisomerase engages the DNA circumfer-backbone phosphates in one strand of duplex DNA (6.5
entially,with the protein in the form of a C-shaped clamp,AÊ ). Because sulfate is a structural analog of phosphate,
essentially as predicted by footprinting studies of thewe suspect that side chain interactions with the sulfates
topoisomerase±DNA interface (Shuman and Turner, 1993;reflect contacts made by topoisomerase with the phos-
Sekiguchi and Shuman, 1994). (ii) It implies conformationphates in DNA. It is noteworthy that the HP1 integrase
flexibility in the free topoisomerase, which must openstructure contains one enzyme-bound sulfate that is
up to accommodate DNA within a cleft of the protein.coordinated by the active site Tyr and the second Arg
This is most likely achieved through domain motionand second His of the RHRH catalytic tetrad (Hickman
about the trypsin-sensitive bridge segment, which iset al., 1997). We posit that the first sulfate is situated at
rendered trypsin-resistant upon DNA binding (Sekiguchia site on vaccinia topoisomerase that would be occupied
and Shuman, 1995). (iii) It places catalytic residues Lys-by the scissile phosphate of the DNA substrate.
220, Arg-223, and His-265 in a position to interact di-
rectly with the scissile phosphate. (iv) It suggests that
A Model of the Topoisomerase±DNA Complex conserved SKxxY motif of type IB topoisomerases inter-
We previously built a model of the interface between acts with thephosphate immediately preceding thescis-
the N-terminal domain of vaccinia topoisomerase (aa sile bond; this phosphate and the upstream deoxyribose
1±77) and the CCCTT target site in which a concave sugar have been shown by modification interference to
face of the domain fit into the major groove of a B-form be important for DNA binding and strand cleavage by
CCCTT-containing duplex such that the 14C and 13C vaccinia topoisomerase (Shuman and Turner, 1993;
Sekiguchi and Shuman, 1994).bases were in proximity to the Tyr-70 and Tyr-72 side
Structure of Eukaryotic Topoisomerase I
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Figure 6. A Model of Vaccinia Topoisomerase Bound to the DNA Target Site
The topoisomerase catalytic domain was docked manually onto a 21 bp B-form CCCTT-containing DNA molecule (colored red) in such a way
as to superimpose the sulfates on the scissile phosphate (highlighted in green) and the preceding phosphate of the CCCTT strand. The
N-terminal topoisomerase domain from residues 1±77 (Sharma et al., 1994) was placed in the major groove in accordance with UV cross-
linking data as described (Sekiguchi and Shuman, 1996). (A) shows a longitudinal view with the recognition sequence (39-pTTCCC-59) to the
right of the scissile phosphate. (B) shows a view down the DNA axis. The images were prepared using the programs MOLSCRIPT and
RASTER3D.
The structure suggests that a precleavage conforma- of the proposed change would be the placement of the
Arg-130 side chain at the scissile phosphate. We alsotional change in the catalytic domain would be neces-
sary to reorient Tyr-274 to attack the scissile phosphate. predict that essential side chain Lys-167, located in the
loop between b strands 2 and 3, will flip into the minorThis is a feature that is apparently shared with several
members of the recombinase family. Reorientation of groove to contact either the scissile phosphate or the
bases of the target site, as noted in Cre-lox (Guo etthe buried tyrosine nucleophile of XerD by simple side
chain rotation was mentioned above. In the lambda in- al., 1997). Kinetic analysis of topoisomerase mutants
suggests that the proposed conformational steps aretegrase catalytic domain, the active site tyrosine is lo-
cated on a flexible segment and is distant from the other perturbed by alanine substitutions at residues Gly-132
and Tyr-136 (located in the protease-sensitive linker be-catalytic residues (Kwon et al., 1997). The structure of
Cre bound noncovalently to lox DNA indicates that the tween helices 2 and 3) and at residue Ser-204 (located
at the proximal margin of helix 5) (Wang et al., 1997;active site tyrosine hydrogen bonds to the phosphate
immediately upstream (59) of the scissile phosphate. In Wittschieben and Shuman, 1997). Ser-204 is conserved
in lambda integrase and Cre recombinase (Figure 3B)going from this state to the covalent intermediate, there
is a shift in the position of the tyrosine-containing helix (Yang and Mizuuchi, 1997).
Chemical footprinting studies of the topoisomerase±(Guo et al., 1997). In the vaccinia topoisomerase±DNA
model, simple rotation of the tyrosine side chain about DNA interface indicate that the enzyme contacts the
phosphodiester backbone along the minor groove ofCa-Cb would not suffice to position it near the scissile
phosphate. We suspect that proper alignment will entail the DNA on the opposite face of the helix from the major
groove contacts made by the N-terminal domain (Seki-movement of helix 8 and the preceding loop segment
into a conformation more like that of the HP1 integrase guchi and Shuman, 1994). As modeled in Figure 6, the
catalytic domain is in proximity to minor groove phos-(Figure 4). A conformational change in the topoisomer-
ase catalytic domain upon DNA binding has been invoked phates identified by ethylation inteference as important
for DNA binding. Although the model was made usingpreviously based on kinetic experiments, mutagenesis,
and partial proteolysis of free versus DNA-bound topo- a canonical B-form helix, it is quite possible that the
DNA as well as the protein undergoes a conformationalisomerase (Stivers et al., 1994; Sekiguchi and Shuman,
1995; Wittschieben and Shuman, 1997). In addition to change upon topoisomerase I binding, which would fa-
cilitate additional contacts. The DNA target site in thethe change in the location of Tyr-274, we propose that
the region from aa 129±137 goes from a disordered Cre-lox cocrystal is bent (Guo et al., 1997). A proposed
model of the XerD±DNA interface also invokes bendingprotease-sensitive state in the free topoisomerase to an
ordered protease-resistant state prior to strand cleav- toward the catalytic domain (Subramanya et al., 1997).
Studies of cellular topoisomerase I have indicated aage (Sekiguchi and Shuman, 1995). A key consequence
Cell
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Figure 7. Topoisomerase and Recombinase: C-Shaped Protein Clamps
The N-terminal domain and catalytic domain of vaccinia topoisomerase (modeled as in Figure 6) are shown next to the structure of Cre
(noncovalent protomer). The structures are aligned with respect to helix 6 (colored in green). The other conserved structural features are
colored in cyan; the b2-b3 loop is in red. Unique structural features of the catalytic domains are colored gray.
preference for binding and cleavage at target sites con- Hence, we suspect that the catalytic domain of cellular
topoisomerase I is structurally similar to its vacciniataining an intrinsic bend (Krogh et al., 1991). In the vac-
cinia case, there is evidence for a post-cleavage alter- counterpart. The topoisomerase catalytic ªpentadº is
conserved in thesecondary and tertiary structures of theation of the conformation of the T residue immediately
59 of the site of covalent adduct formation (Sekiguchi site-specific recombinases, despite scant amino acid
sequence similarity overall. The implication is that theand Shuman, 1996b).
catalytic domains of type IB topoisomerases and site-
specific recombinases derive from a common ancestralEvolution of Topoisomerase I and
Site-Specific Recombinases enzyme capable of transesterification to the 39 phos-
phate at the site of DNA strand scission.Prior studies have underscored the functional similari-
ties between vaccinia DNA topoisomerase and the re- The catalytic domains of vaccinia topoisomerase and
Cre recombinase are linked to N-terminal domains thatcombinase family, to wit: (i) vaccinia topoisomerase
catalyzes the resolution of Holliday junctions with high interact with the DNA target site in the major groove
(Sekiguchi and Shuman,1996a, 1997; Guo et al., 1997). Aefficiency in vitro (Sekiguchi et al., 1996), (ii) in vivo
expression of vaccinia topoisomerase in an integrase- similar role is likely for the N-terminal domain of lambda
integrase (Tirumalai et al.,1997). In the Cre-lox cocrystal,minus lambda lysogen complements excision via topo-
isomerase-catalyzed recombination between CCCTT- and in our model of the topoisomerase on DNA, the
enzymes encompass the DNA duplex within a C-shapedlike sites flanking attL and attR (Shuman, 1989, 1991b),
and (iii) protein±protein interactions between DNA-bound protein clamp (Figure 7). Structural conservation of the
catalytic domains is apparent in Figure 7. Here, the topo-topoisomerase molecules facilitate intramolecular syn-
apsis of duplex DNA (Shuman et al., 1997). Although it isomerase and Cre structures are shown such that the
(K/H)xxR helices (colored green) are superimposable.has beenspeculated that there might be locally conserved
structural motifs in eukaryotic topoisomerase I and site- Conserved helices and loops are colored in cyan. The
b2±b3 loops containing the topoisomerase catalytic ly-specific recombinases (Wittschieben and Shuman, 1997),
the finding of global structural similarity between a eu- sine are highlighted in red. The nonconserved portions
of the catalytic domains are shown in gray (Figure 7).karyotic topoisomerase I and recombinases had not
been anticipated, because computer-based searches Vaccinia topoisomerase contains a unique set of helices
near the carboxyl end of the catalytic domain that arefailed to reveal any amino acid sequence conservation.
The delineation of structure-function relationships by missing from Cre. Deletion mutagenesis indicates that
the C-terminal helices are important for topoisomerasemutagenesis is well advanced with vaccinia topoisomer-
ase, more so than with cellular topoisomerase I or any activity (Wang and Shuman, 1997). Cre contains a unique
C-terminal tail projecting away from the catalytic coreof the recombinase family members. A constellation of
five catalytic side chains on the vaccinia topoisomerase (Figure 7); this tail mediates Cre±Cre multimerization
(Guo et al., 1997). HP1 integrase also contains a unique(Arg-130, Lys-167, Lys-220, Arg-223, His-265; or RKKRH)
is strictly conserved in eukaryotic type IB enzymes. C-terminal tail extending away from the body of the
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asymmetric unit. Diffraction data were collected with flash-frozenprotein that mediates dimerization (Hickman et al.,
crystals. The crystals were serially transferred to reservoir buffer1997). Formation of the Cre-lox synaptic complex in-
containing increasing amounts of glycerol to attaina final concentra-volves extensive protein-protein interactions between
tion of 25% glycerol; they were then flash frozen in a stream of
the four DNA-bound recombinase protomers. In con- nitrogen at 21658C. The native set data was collected at the Cornell
trast, eukaryotic type I topoisomerases are believed to High Energy Synchrotron Source (CHESS). Heavy atom derivatives
were obtained by soaking the crystals for the times specified in 100act as monomers. There is no similarity at all between
mM sodium citrate (pH 5.6), 61% (NH4)2SO4 containing one of thethe N-terminaldomain of vaccinia topoisomerase (which
following heavy atom solutions: 1.5 mM thimerosal for 4 hr, 1 mMconsists of five antiparallel b sheets and two short a
KAu(CN)2 for 14 hr, or 1.5 mM HgCl2 for 3 hr. Diffraction data for thehelices) and the N-terminal domain of Cre (composed
heavy atom derivatives were collectedon an R-AxisIIC imagingplate
of five a helices) (Sharma et al., 1994; Guo et al., 1997) detector mounted on a Rigaku 200 HB X-ray generator. Heavy atom
(Figure 7). It is noteworthy that the carboxyl catalytic sites were identified by using the program SHELXS (Sheldrick et al.,
1993) and difference Fourier maps. The initial MIR phases weredomains of vaccinia topoisomerase, lambda integrase,
calculated with the program MLPHARE and the CCP4program suiteand Cre recombinase are capable of recognizing their
(Collaborative Computational Project, Number 4, 1994). The MIRrespective target sites per se, albeit with much reduced
phases had a mean figure of merit of 0.65 to 3.2 AÊ and were improvedaffinity compared to the full-sized proteins (Hoess et al.,
by solvent flattening and histogram matching with the program DM.
1990; Tirumalai et al., 1997; Cheng and Shuman, 1998). A model was built with the program O (Jones et al., 1991). Successive
In the case of topoisomerase and Cre, deletion of the rounds of rebuilding and refinement with the program X-PLOR
(Brunger, 1991) were followed by a bulk solvent correction to theN-terminal domain results in reduced activity in strand
data. Simulated annealing omit electron density maps were usedcleavage (Hoess et al., 1990; Cheng and Shuman, 1998).
to check the model. Statistics are presented in Table 1.We hypothesize that the distinct specificities of these
enzymes may be achieved through conformational acti-
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